Open Beta
MetriLume

US marketsVVOS

SEC-sourced researchBeta

VVOS

Vivos Therapeutics, Inc.

Company comparison ↗

Data passport

CIK
0001716166
Exchange
Nasdaq
Business activity
— · SIC 3841
Financial inputs
6/6
Filing date
Oct 1, 2026
SEC registry record
Operating company

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 15,031,000.0000 USD; December 2025: 17,443,000.0000 USD17.4M USD0 USD0December 2024December 2025
VVOS · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202415,031,000.0000Apr 15, 2026
December 202517,443,000.0000Apr 15, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202517,443,000.0000-21,170,000.0000-15,263,000.000025,152,000.000026,702,000.0000Apr 15, 2026
December 202415,031,000.0000-11,136,000.0000-12,691,000.000015,284,000.00007,330,000.0000Apr 15, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$17.44MDecember 2025Apr 15, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$15.03MDecember 2024Apr 15, 202610-K
Net incomeNetIncomeLoss-$21.17MDecember 2025Apr 15, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$15.26MDecember 2025Apr 15, 202610-K
Total assetsAssets$25.15MDecember 2025Apr 15, 202610-K
Total liabilitiesLiabilities$26.7MDecember 2025Apr 15, 202610-K

New filings

Explore methodology ↗